Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study

Kudo M.Tsuchiya KaoruYU-YUN SHAOFinn Richard S.Galle Peter R.Ducreux MichelANN-LII CHENGYamashita TatsuyaKoga HironoriTake RyosukeYamada KyokoAsakawa TakashiNakagawa YukiIkeda Masafumi2024-07-192024-07-192023-01-0122351795https://scholars.lib.ntu.edu.tw/handle/123456789/719899trueImpact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Studyjournal article2-s2.0-85187477927